 |
JOURNAL TOOLS |
| Publishing options |
| eTOC |
| To subscribe |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Publication history |
| Reprints |
| Permissions |
| Cite this article as |
| Share |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW
Panminerva Medica 2018 December;60(4):174-84
DOI: 10.23736/S0031-0808.18.03542-5
Copyright © 2018 EDIZIONI MINERVA MEDICA
language: English
Therapy for relapsed multiple myeloma
Mohammed A. ALJAMA, M. Hasib SIDIQI, David DINGLI ✉
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
Despite significant progress in our understanding and the development of novel therapies, most patients with multiple myeloma will experience relapse of their disease. Therapy of relapsed myeloma has improved due to the availability of novel agents that are highly active against the disease. However, the selection of therapy can be challenging due to the emergence of toxicities, comorbidities and frailty. In the following we discuss our approach to the treatment of the patient with relapsed myeloma.
KEY WORDS: Recurrence - Multiple myeloma - Therapeutics